Kelly Lawrence W & Associates Inc Gilead Sciences, Inc. Transaction History

Kelly Lawrence W & Associates Inc

  • $430 Million
  • Q3 2024

A detailed history of Kelly Lawrence W & Associates Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Kelly Lawrence W & Associates Inc holds 9,405 shares of GILD stock, worth $852,939. This represents 0.18% of its overall portfolio holdings.

Number of Shares
9,405
Previous 10,300 8.69%
Holding current value
$852,939
Previous $706,000 11.61%
% of portfolio
0.18%
Previous 0.16%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$66.59 - $83.99 $59,598 - $75,171
-895 Reduced 8.69%
9,405 $788,000
Q2 2024

Aug 13, 2024
SELL
$63.15 - $72.88 $6,188 - $7,142
-98 Reduced 0.94%
10,300 $706,000
Q1 2024

May 15, 2024
SELL
$71.58 - $87.29 $45,310 - $55,254
-633 Reduced 5.74%
10,398 $761,000
Q3 2023

Nov 14, 2023
SELL
$73.94 - $80.67 $7,394 - $8,067
-100 Reduced 0.9%
11,031 $826,000
Q2 2023

Aug 14, 2023
SELL
$76.01 - $86.7 $60,808 - $69,360
-800 Reduced 6.71%
11,131 $857,000
Q1 2023

May 15, 2023
BUY
$77.31 - $88.08 $158,485 - $180,564
2,050 Added 20.75%
11,931 $989,000
Q3 2022

Nov 15, 2022
SELL
$59.54 - $68.01 $98,181 - $112,148
-1,649 Reduced 14.3%
9,881 $610,000
Q2 2022

Aug 15, 2022
SELL
$57.72 - $65.01 $80,808 - $91,014
-1,400 Reduced 10.83%
11,530 $713,000
Q1 2022

May 16, 2022
SELL
$57.92 - $72.58 $131,768 - $165,119
-2,275 Reduced 14.96%
12,930 $769,000
Q4 2021

Feb 11, 2022
SELL
$64.88 - $73.64 $45,416 - $51,548
-700 Reduced 4.4%
15,205 $1.1 Million
Q3 2021

Nov 15, 2021
SELL
$67.69 - $73.03 $32,152 - $34,689
-475 Reduced 2.9%
15,905 $1.11 Million
Q2 2021

Aug 16, 2021
SELL
$63.47 - $69.35 $19,041 - $20,805
-300 Reduced 1.8%
16,380 $1.13 Million
Q1 2021

May 17, 2021
BUY
$60.0 - $68.46 $648,300 - $739,710
10,805 Added 183.91%
16,680 $1.08 Million
Q4 2020

Feb 12, 2021
SELL
$56.65 - $64.55 $882,607 - $1.01 Million
-15,580 Reduced 72.62%
5,875 $342,000
Q1 2020

May 14, 2020
SELL
$62.63 - $80.22 $32,880 - $42,115
-525 Reduced 2.39%
21,455 $1.6 Million
Q4 2019

Feb 14, 2020
SELL
$61.62 - $67.78 $36,972 - $40,668
-600 Reduced 2.66%
21,980 $1.43 Million
Q3 2019

Nov 14, 2019
BUY
$62.51 - $69.0 $18,753 - $20,700
300 Added 1.35%
22,580 $1.43 Million
Q2 2019

Aug 14, 2019
SELL
$61.87 - $69.38 $26,294 - $29,486
-425 Reduced 1.87%
22,280 $1.51 Million
Q4 2018

Feb 14, 2019
SELL
$60.54 - $79.0 $484,320 - $632,000
-8,000 Reduced 26.05%
22,705 $1.42 Million
Q3 2018

Nov 14, 2018
BUY
$71.28 - $78.92 $78,408 - $86,812
1,100 Added 3.72%
30,705 $2.37 Million
Q3 2017

Nov 15, 2017
BUY
$72.11 - $85.47 $2.13 Million - $2.53 Million
29,605
29,605 $2.4 Million

Others Institutions Holding GILD

# of Institutions
1,926
Shares Held
993M
Call Options Held
10.5M
Put Options Held
9.75M
View Full List

About GILEAD SCIENCES, INC.

GILD Quotes by TradingView
  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $114B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Kelly Lawrence W & Associates Inc Portfolio

Follow Kelly Lawrence W & Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kelly Lawrence W & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Kelly Lawrence W & Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email